MedTrace Logo

TrAnsCatHeter Intravascular Ultrasound Energy deliVery for rEnal Denervation (ACHIEVE)

NCT01789918 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2018-07-06

No results posted yet for this study

Summary

The ACHIEVE study is a single-arm, open-label, prospective, post-market follow-up study to include up to one hundred (100) eligible patients as defined within the clinical investigational plan, with a twelve month follow-up period. The ACHIEVE study was originally designed in accordance with the 2007 ESH ESC guidelines for resistant hypertension.

Conditions

  • Resistant Hypertension

Interventions

DEVICE

PARADISE percutaneous renal denervation

Intravascular ultrasound emission

Sponsors & Collaborators

  • ReCor Medical, Inc.

    lead INDUSTRY

Principal Investigators

  • Thomas Zeller, Professor · Universitäts-Herzzentrum Freiburg • Bad Krozingen

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-09
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • Germany
  • Netherlands
  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01789918 on ClinicalTrials.gov